1. Introduction {#sec1-cancers-10-00179}
===============

Acute myeloid leukemia (AML) is a disease that primarily affects adults aged 65 years and above; the median age of patients at diagnosis is 68 years \[[@B1-cancers-10-00179]\]. The estimated five-year survival in older adults with AML is poor at less than 5% \[[@B2-cancers-10-00179]\]. The dismal prognosis in an older population is attributed to a variety of host and disease factors including high prevalence of comorbidity, frailty, poor functional status, unfavorable cytogenetics, greater resistance to leukemia-directed treatment, and higher rate of treatment-related toxicities \[[@B3-cancers-10-00179],[@B4-cancers-10-00179]\]. Older patients are also more likely to have secondary AML related to antecedent hematologic disorders with consequent poor response to standard chemotherapy \[[@B5-cancers-10-00179]\]. Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative therapy for patients with intermediate- or high-risk AML or those who fail to enter complete remission after one to two cycles of induction chemotherapy \[[@B6-cancers-10-00179]\]. Older patients, historically, had not been considered for allo-HCT due to frequent comorbidities and perceived higher risk of treatment-related mortality and non-relapse mortality \[[@B7-cancers-10-00179]\]. Recently, however, there is increasing data that support the utility of allo-HCT in fit older patients after intensive chemotherapy resulting in improvement of outcomes \[[@B8-cancers-10-00179]\]. Despite this, less than 6% of older patients receive allo-HCT, which is partially attributed to the reluctance of physicians to transplant these patients and the challenges associated with the selection of transplant candidates \[[@B9-cancers-10-00179]\]. [Figure 1](#cancers-10-00179-f001){ref-type="fig"} shows the possible barriers to hematopoietic stem cell transplantation in older patients with AML.

Myeloablative conditioning regimens are frequently used in allo-HCT, but they are sometimes associated with an unacceptable rate of treatment-related mortality in older adults. The development of reduced intensity and non-myeloablative conditioning regimens that are associated with lower rates of treatment-related toxicity and mortality, in place of myeloablative conditioning regimens, has allowed a higher number of older patients with AML to receive allo-HCT \[[@B10-cancers-10-00179]\]. In addition to this, the availability of various donor sources increases the access and eligibility for hematopoietic stem cell transplantation. In the past, the utilization of allo-HCT relied heavily and almost exclusively on stem cells harvested from matched sibling donors. However, the likelihood of finding a matched sibling donor is lower in the older AML population, as most of their sibling donors are older themselves and may have comorbidities that prohibit them from being donors. The alternative is usually a matched unrelated donor, which may pose difficulties for racial/ethnic minorities due to lower rates of locating acceptable donors in worldwide registries \[[@B11-cancers-10-00179]\]. Because of this, other donor sources such as mismatched unrelated donors, haploidentical donors, and umbilical cord blood, are becoming increasingly available and utilized. In this review, we describe published studies that may guide the appropriate selection of older patients as transplant candidates. We also discuss the benefits and risks associated with allo-HCT, conditioning regimen choice, and stem cell transplant sources as they relate to conduct of stem cell transplantation in older patients.

2. Selection of Candidates for Hematopoietic Stem Cell Transplantation {#sec2-cancers-10-00179}
======================================================================

According to the Center for International Blood Marrow Transplant Research (CIBMTR) database, the number of patients with AML aged 70 years and over who received allo-HCT increased from 0.1% in 2000 to 3.9% in 2013 \[[@B10-cancers-10-00179]\]. This parallels the number of institutions that perform allo-HCT in older patients, which increased from 65 in 2000 to 93 in 2013 \[[@B10-cancers-10-00179]\]. Some studies suggest improvements in outcomes of older patients with AML who received allo-HCT \[[@B10-cancers-10-00179],[@B12-cancers-10-00179]\]. In the aforementioned CIBMTR database study, two-year progression-free and overall survival after allo-HCT improved from 22% and 26% during 2000--2007 to 32% and 39% during 2008--2013, respectively. There was no change in treatment-related mortality between the two time periods. In a European Group for Blood and Marrow Transplantation (EBMT) registry data study that included 1,333 patients aged 50 years and over with secondary AML and myelodysplastic syndrome (MDS) who received allo-HCT, there was no significant difference in overall survival and non-relapse mortality by age groups \[[@B13-cancers-10-00179]\]. Four-year overall survival was 34% and 27%, respectively, in the patients aged 50 to 60 years and those over 60 years (*p* = 0.23). Four-year non-relapse mortality rate was 36% and 39% (*p* = 0.39), respectively \[[@B13-cancers-10-00179]\]. These studies therefore support the feasibility, safety, and potential efficacy of allo-HCT in older patients.

Historically, older patients with AML were excluded from consideration of hematopoietic stem cell transplantation solely based on chronological age. However, age alone is not a reliable predictor of a patient's ability to tolerate intensive chemotherapy or allo-HCT. Instead, other factors such as comorbidities, functional status, and psychosocial support, in addition to disease characteristics need to be taken into account when considering treatment tolerance and outcomes \[[@B14-cancers-10-00179],[@B15-cancers-10-00179],[@B16-cancers-10-00179]\]. For example, Sorror and colleagues developed the hematopoietic cell transplantation comorbidity index (HCT-CI) that may help risk stratify older patients with AML based on a number of medical comorbidities such as cardiac disease, cerebrovascular disease, diabetes, inflammatory bowel disease, pulmonary disease, psychiatric illness, obesity, infection, and other domains \[[@B17-cancers-10-00179]\]. Patients are categorized into three risk groups: low (a score of 0), moderate (a score of 1 to 2), and high (a score of 3 or more). The two-year non-relapse mortality in the low, moderate, and high-risk groups was 14%, 21%, and 41%, respectively. The corresponding two-year overall survival was 71%, 60%, and 34%, respectively \[[@B17-cancers-10-00179]\]. This tool therefore helps guide transplant evaluation, especially in older patients with a prevalence of these comorbidities \[[@B17-cancers-10-00179]\]. There are also efforts to combine the HCT-CI with cytogenetic and molecular profiles or with clinical assessments to create an AML composite model. For example, Muffly and colleagues incorporated the HCT-CI as part of a geriatric assessment that included measures of frailty, functional status, and markers of inflammation/nutritional status \[[@B18-cancers-10-00179]\]. The authors showed that the combination of geriatric assessment measures (specifically instrumental activity of daily living, gait speed, mental health, and C-reactive protein) and HCT-CI predicted poor outcomes in patients aged 60 years and over that underwent allo-HCT \[[@B18-cancers-10-00179]\]. A geriatric assessment may also predict treatment toxicities and guide supportive care interventions, although further studies are needed in AML, especially as related to fitness for stem cell transplantation \[[@B19-cancers-10-00179],[@B20-cancers-10-00179],[@B21-cancers-10-00179]\].

To improve the selection of candidates for allo-HCT, it is important to assess the physiological age and not rely on chronological age alone. The use of available tools such as the HCT-CI and geriatric assessment can help inform the risk of treatment-related mortality and overall survival \[[@B22-cancers-10-00179]\]. A multi-disciplinary approach is needed when evaluating for transplant candidacy in this patient population with complex needs \[[@B23-cancers-10-00179],[@B24-cancers-10-00179]\].

3. Conditioning Regimens {#sec3-cancers-10-00179}
========================

The choice of a conditioning regimen is an integral part of allo-HCT with influence on disease control and transplant-related toxicities. The CIBMTR classifies the conditioning regimens into myeloablative, reduced-intensity, and non-myeloablative categories \[[@B25-cancers-10-00179],[@B26-cancers-10-00179]\]. Generally, myeloablative regimens induce irreversible pancytopenia and patients require support with hematopoietic stem cells. On the other hand, non-myeloablative regimens induce minimal cytopenias and patients do not require hematopoietic stem cell support. Reduced-intensity regimens fall in between myeloablative and non-myeloablative regimens, resulting in variable degrees of marrow ablation \[[@B25-cancers-10-00179],[@B26-cancers-10-00179]\].

In older patients with AML, treatment with a myeloablative regimen for allo-HCT is associated with higher treatment-related mortality rates compared to those who did not undergo transplant \[[@B27-cancers-10-00179]\]. [Table 1](#cancers-10-00179-t001){ref-type="table"} lists the studies that compared the various conditioning regimens and included some patients aged 60 and over \[[@B28-cancers-10-00179],[@B29-cancers-10-00179],[@B30-cancers-10-00179],[@B31-cancers-10-00179],[@B32-cancers-10-00179],[@B33-cancers-10-00179]\]. It is worth noting that the upper age limit of patients included is usually 70 or lower. In the Dutch-Belgian Hemato-Oncology Cooperative Group and the Swiss Group for Clinical Cancer Research (HOVON-SAKK) collaborative study of 1032 patients, treatment-related mortality was higher in patients who underwent allo-HCT using a myeloablative conditioning regimen compared to those who did not undergo transplant (25% versus 4%, *p* \< 0.01) \[[@B27-cancers-10-00179]\]. This risk was higher in the older age group \[Hazard Ratios (HR) 6.1, 95% Confidence Interval (CI) 3.0--12.2\], compared to the younger age group (HR 2.7, 95% CI 1.5--4.9). Of note, only patients up to the age 55 were included in the study. Due to the high treatment-related mortality, attention has been shifted toward using reduced intensity and non-myeloablative conditioning regimens. A number of studies demonstrated a decrease in treatment-related mortality and toxicities including mucositis, hemorrhagic cystitis, cytomegalovirus infections (CMV), time to engraftment, and need for transfusions \[[@B28-cancers-10-00179],[@B31-cancers-10-00179],[@B34-cancers-10-00179]\].

One concern, however, is the higher relapse rate associated with reduced-intensity regimens compared to myeloablative conditioning regimens \[[@B30-cancers-10-00179]\]. It was postulated that the higher rates of relapse could be secondary to the decreased cytotoxic anti-leukemia effects, allowing persistence of quiescent leukemia stem cells or more overt minimal residual disease \[[@B35-cancers-10-00179]\]. Published studies have reported variable results, with some demonstrating comparable overall survivals in those who received myeloablative and reduced-intensity conditioning regimens \[[@B32-cancers-10-00179],[@B33-cancers-10-00179],[@B36-cancers-10-00179]\], and some reporting higher overall survivals in those who received myeloablative conditioning regimens \[[@B31-cancers-10-00179],[@B37-cancers-10-00179]\]. The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0901 study is the largest phase III randomized clinical trial (RCT) comparing outcomes by conditioning intensity in patients with high-risk AML and MDS \[[@B31-cancers-10-00179]\]. In this RCT, 272 patients (median age 54.8 years, range 21.9--66.0) with a HCT-CI score of 4 or less were randomized to receive myeloablative or reduced-intensity conditioning regimens \[[@B31-cancers-10-00179]\]. The trial was closed to accrual early due to a large difference noted in the relapse-free survival favoring the myeloablative arm. In patients with AML, compared to the reduced-intensity arm, the myeloablative arm has superior relapse-free survival (65.2% versus 45.3%; *p* \< 0.01) and overall survival (76.4% versus 63.4%; *p* = 0.04) at 18 months. Treatment-related mortality at 18 months was higher in the myeloablative group compared to the reduced-intensity group (15.8% versus 4.4%; *p* \< 0.02). Although treatment-related mortality was lower in the reduced-intensity group, this difference seems to have been offset by an increase in relapse rate and therefore a lower overall survival rate. Whether these results would be similar in studies examining only older recipients has not been explored in depth. In the BMT CTN 0901 study, the HRs for overall survival for myeloablative conditioning versus reduced-intensity conditioning did not appear to be different by age subgroups (≥55 versus \<55 years, interaction *p* = 0.42).

Another large multicenter, retrospective study from the EBMT registry included 878 patients with AML or MDS who received allo-HCT utilizing myeloablative, reduced-intensity, or non-myeloablative conditioning regimens from 1998 to 2004 \[[@B33-cancers-10-00179]\]. The myeloablative group was further divided into conventional (cyclophosphamide with high-dose busulfan) or hyperintense myeloablative (additional cytotoxic agents such as high-dose melphalan, thiotepa, etopisode, or cytarabine to conventional myeloablative regimen) groups. The follow-up period was up to 7 years after transplantation. In patients aged 50 and over, non-relapse mortality in the hyperintense myeloablative, conventional myeloablative, reduced-intensity, and non-myeloablative groups were 51%, 41%, 24%, and 31% (*p*-value comparing both myeloablative regimens versus both reduced-intensity and non-myeloablative group was \<0.01), respectively. Relapse rates were 28%, 22%, 29%, and 49% (*p* = 0.20), and overall survivals were 21%, 41%, 56%, and 27% (*p*-value comparing reduced-intensity with other groups was \<0.01), respectively. On multivariate analyses, older age (\>50 versus ≤50 years) was significantly associated with a higher non-relapse mortality (HR 2.5, 95% CI 1.7--3.5) and lower overall survival (HR 1.9, 95% CI 1.1--3.1), but not relapse. As opposed to the BMT CTN 0901 study, this large retrospective study suggests potential lower non-relapse mortality, comparable relapse rate, and higher overall survival with reduced-intensity compared to conventional myeloablative conditioning regimens in older patients. Therefore, whether reduced-intensity versus myeloablative or non-ablative regimens lead to better survival in older patients with AML remains uncertain, and it is unlikely a randomized trial in older patients will be accomplished to answer this given the concern about high mortality rates with ablative regimens. Finally, a meta-analysis of eight studies included 6,464 AML/MDS patients who received myeloablative and reduced-intensity regimens. Of note, the BMT CTN 0901 was not included in this meta-analysis \[[@B38-cancers-10-00179]\]. There was significant heterogeneity in the characteristics of patients included; patients in the reduced-intensity group were older, had lower HCT-CI scores, and had higher-risk disease based on cytogenetics. This reflected a selection bias with sicker patients being more likely to receive reduced-intensity regimens and healthier patients being more likely to receive myeloablative regimens. Despite this, there was no significant difference between the two groups in overall survival \[Odds Ratio (OR) 0.96, 95% CI 0.84--1.08)\], event-free survival (OR 0.88, 95% CI 0.77--1.00), or non-relapse mortality (OR 0.99, 95% CI 0.87--1.13).

Taken together, the BMT CTN 0901 study suggests that myeloablative conditioning regimens should be the standard of care for patients who are considered fit enough to tolerate this degree of intensity. For those who are perceived to be unfit for myeloablative regimens, reduced-intensity or non-myeloablative regimens may be considered. Alternatively, clinical trials or systemic agents such as chemotherapy without a transplant are reasonable in an unfit population. This population typically has a higher burden of comorbidities and decreased functional and performance status.

4. Donor Sources for Older Transplant Recipients {#sec4-cancers-10-00179}
================================================

Matched-related sibling donors are the main donor source for allo-HCT. However, the sibling match probability is decreased in older adults (28% in 65--74 year olds versus 39% in 45--64 year olds) \[[@B39-cancers-10-00179]\]. Recent advances in HLA-typing have increased the pool of donor sources to include matched-unrelated, umbilical cord blood, haploidentical donors, and mismatched-unrelated donors ([Table 2](#cancers-10-00179-t002){ref-type="table"}). The use of alternative donor sources increases the recipient eligibility pool and may reduce the time from diagnosis to transplant. Based on the National Marrow Donor Program (NMDP) registry, the likelihood of finding a matched-unrelated donor is 75% in white patients of European descent, 46% in white patients of Middle Eastern or North African descent, 16 to 19% in African Americans, and 27 to 52% in Hispanics, Asians, Pacific Islanders, and Native Americans \[[@B40-cancers-10-00179]\]. Similarly, the likelihood of finding sufficient cord blood units (5/6 or 6/6 HLA-matched) is higher in patients of White European descent.

Studies comparing patients who received allo-HCT using matched-related donors versus matched-unrelated donors demonstrated comparable outcomes, although compared to young adults, older patients may have worse outcomes \[[@B45-cancers-10-00179],[@B46-cancers-10-00179]\]. In a single-institution retrospective analysis of 405 patients (median age 54.5 years, range 20--72, 13% had a 9/10 HLA-matched donor) with various hematologic malignancies, outcomes including non-relapse mortality, relapse, and overall survival were not different in the matched-related and matched-unrelated donor groups \[[@B45-cancers-10-00179]\]. Nevertheless, older patients had worse overall survival on multivariable analysis (≥50 versus \<50 years; HR 1.4, 95% CI 1.0--1.9), but not non-relapse mortality and relapse. In a retrospective analysis of 368 older patients with AML (median age 57 years, range 50--73) from transplant centers of the German Cooperative Transplant Study Group, event-free survival, relapse, and overall survival were also similar between matched-related and matched-unrelated donors \[[@B46-cancers-10-00179]\]. In this study, age as a continuous variable was not associated with event-free or overall survivals on multivariable analyses. However, older age was associated with higher relapse rate (HR 1.0, 95% CI 1.0--1.1).

The effect of donor age on transplant outcomes is an area of investigation. Some studies suggest a possible survival advantage when younger sibling donors were used as compared to older donors \[[@B47-cancers-10-00179]\], while others did not show any difference in outcomes. For example, in a single-center retrospective study that included 442 patients (median 48, range 7--68), compared to patients who utilized a matched-unrelated donor, relapse rate was higher in those who utilized a matched-related donor aged 60 years and over (HR 4.41, 95% CI 1.52--12.80). This difference was not noted in patients who utilized a matched sibling donor aged less than 60 years of age (HR 1.18, 95% CI 0.55--1.55) \[[@B48-cancers-10-00179]\]. The difference in outcomes may be due to the decreased allo-reactivity of older donor T cells that lead to a decrease in anti-leukemia effects \[[@B49-cancers-10-00179]\]. In a second retrospective study using the EBMT registry that included 714 adults with AML (median age at transplant 61.4 years, range 55--74), outcomes such as relapse, non-relapse mortality, leukemia-free survival, and overall survival were similar in patients who received allo-HSCT from a matched-unrelated donor or a matched-related donor \[[@B50-cancers-10-00179]\]. Taken together, matched-related donors and matched-unrelated donors are still the preferred donor sources, and the choice for one versus another depends on other factors related to the donor (age, smoking status, and comorbidity) and to patient-donor compatibility (7/8 or 8/8 HLA-matched, gender, ABO compatibility, and CMV status) \[[@B51-cancers-10-00179]\].

A haploidentical transplantation is a technique that was initially limited by high transplant-related morbidity and mortality and engraftment failures \[[@B52-cancers-10-00179],[@B53-cancers-10-00179]\]. With improvement in the depletion of T cells from the graft and unmanipulated in vivo regulation of T cells through post-infusion cyclophosphamide, haploidentical transplant is increasingly being utilized \[[@B43-cancers-10-00179],[@B54-cancers-10-00179]\]. It is a very attractive option given most patients will have a relative (parents, siblings, or children) with one HLA-matching haplotype. In a retrospective study of 36 patients aged 60 and over with AML, three-year progression-free and overall survivals were 31% and 38%, respectively. In addition, older age was not associated with non-relapse morality, progression-free survival, and overall survival (60 to 69 and 70 to 75 versus 50 to 59). These were comparable to the study by the German Cooperative Transplant Study Group which utilized matched-related and matched-unrelated donors \[[@B46-cancers-10-00179]\]. Currently, there is no RCT that compares the use of a haploidentical transplantation versus matched-related or unrelated transplant in older patients. A recently published retrospective study in 127 older patients with AML and MDS compared haploidentical transplantation with allo-HCT using matched-related or matched-unrelated donors. In the match-related, match-unrelated, and haploidentical groups, there were no significant differences in the two-year non-relapse mortality (17%, 23%, and 9%), relapse (32%, 34%, and 33%), and overall survival (62%, 55%, and 67%) \[[@B55-cancers-10-00179]\]. Other studies in AML and MDS not limited to older patients also showed similar findings \[[@B42-cancers-10-00179],[@B56-cancers-10-00179],[@B57-cancers-10-00179],[@B58-cancers-10-00179]\]. Therefore, existing studies support the use of haploidentical transplantation as an acceptable alternative to matched-related or unrelated transplant, especially in those who do not have readily available matched donors.

Umbilical cord blood transplantation is another reasonable alternative to matched-related and unrelated donor transplantation in the absence of available donors. Some of the benefits of cord blood transplantation include rapid availability and greater tolerance of HLA disparity \[[@B59-cancers-10-00179],[@B60-cancers-10-00179]\]. However, as compared to haploidentical transplantation, cord blood transplantation is less utilized due to high rates of graft failure and delayed immune reconstitution. Nevertheless, it is feasible in older patients with AML, as shown in multiple studies \[[@B44-cancers-10-00179],[@B61-cancers-10-00179],[@B62-cancers-10-00179]\]. In the CIBMTR Eurocord retrospective analysis that included 441 patients that received allo-HCT utilizing matched-related donors and 205 patients utilizing cord blood (over age 50), the transplant-related mortality was higher in the cord blood group than the 8/8 matched-unrelated donor group (35% versus 27%, *p* = 0.05), but no different than the 7/8 matched-unrelated donor group (35% versus 41%, *p* = 0.30) \[[@B61-cancers-10-00179]\]. Three-year overall survival was lower in the cord blood group compared to the 8/8 matched-unrelated donor group (30% versus 43%, *p* \< 0.01), and comparable to the 7/8 matched-unrelated donor group (30% versus 37%, *p* = 0.25).

5. Graft-Versus-Host Disease in the Older Transplant Patient {#sec5-cancers-10-00179}
============================================================

Graft-versus-host disease (GVHD) is the most common transplant-related complication that affects patients who have undergone hematopoietic stem cell transplantation. GvHD occurs when the donor T-cells attack recipient tissues, affecting organs such as the skin, mouth, eyes, joints, gastrointestinal tract, liver, and lung. Acute GVHD generally occurs shortly after transplantation (within 100 days), whereas chronic GVHD typically occurs beyond 100 days of transplantation \[[@B63-cancers-10-00179]\]. However, there are overlap features where acute GvHD may occur after 100 days and vice versa. A number of studies have shown that the risk of GVHD is increased with age \[[@B41-cancers-10-00179],[@B64-cancers-10-00179],[@B65-cancers-10-00179]\]. GVHD is associated with decreased relapse risk due to graft-versus-leukemia effects, but not survival due to its associated treatment-related morbidity and mortality. Compared to their younger counterparts, older patients are especially susceptible to the consequences of GVHD due to their baseline lower physiologic reserve. In addition, GVHD can significantly affect quality of life, which is an important consideration in older patients \[[@B66-cancers-10-00179],[@B67-cancers-10-00179],[@B68-cancers-10-00179],[@B69-cancers-10-00179]\]. Therefore, GVHD is an important factor when considering the conditioning regimens and donor sources as they are associated with variable risks of GVHD, which correlates with poor quality of life. One study suggests that older patients experience worse physical well-being but better social well-being compared to their younger counterparts \[[@B70-cancers-10-00179]\]. Other studies are mixed suggesting that older patients may achieve better, comparable, or worse QoL than younger patients \[[@B71-cancers-10-00179],[@B72-cancers-10-00179],[@B73-cancers-10-00179]\].

Compared to reduced-intensity or non-myeloablative regimens, myeloablative regimens have a higher incidence of acute and chronic GVHD, which is an important factor contributing to its high treatment-related morbidity and mortality rates \[[@B74-cancers-10-00179],[@B75-cancers-10-00179]\]. In terms of donor sources, HLA-mismatched unrelated donors have the highest incidence of GVHD. Haploidentical transplantation has comparable or lower GVHD rates than matched-related donor transplantation \[[@B42-cancers-10-00179],[@B76-cancers-10-00179],[@B77-cancers-10-00179],[@B78-cancers-10-00179]\]. Cord blood transplantation has a lower incidence of GVHD compared to match-related and unrelated donors \[[@B79-cancers-10-00179],[@B80-cancers-10-00179]\]. Graft source (bone marrow versus peripheral-blood stem cells) also contributes to differing rates of GVHD, with a higher rate of chronic GVHD noted with peripheral-blood stem cell grafts \[[@B81-cancers-10-00179],[@B82-cancers-10-00179]\]. However, engraftment failure is more common when a bone marrow graft is utilized, and relapse rates appear comparable.

High-dose steroids are typically the first-line of treatment for both acute and chronic GVHD. Steroids are associated with a myriad of side-effects such as hypertension, hyperglycemia, confusion/delirium, infections, bone loss, and easy bruising that can be problematic in older adults. Therefore, there is a need to balance the efficacy of steroids for controlling GVHD and the risks of steroids in this population. Steroid sparing agents can be utilized, but these may also be poorly tolerated in an older population due to immune suppression effects. Newer oral agents with activity in GVHD may be better tolerated in older patients (e.g., Janus kinase/JAK or Bruton's tyrosine kinase/BTK inhibitors), but these have not been systematically studied in older patients \[[@B83-cancers-10-00179],[@B84-cancers-10-00179],[@B85-cancers-10-00179]\].

6. Post-Transplant Relapse {#sec6-cancers-10-00179}
==========================

There are several strategies used in the post-transplant setting to prevent relapse of AML. This is especially important in older patients with AML given high rates of relapse. The first approach is typically reducing the doses of immunosuppressive agents to enhance graft versus leukemia effect. However, this can be difficult in patients with ongoing GVHD. Donor lymphocyte infusion is another strategy that can be given when there is increasing mixed-chimerism or in the setting of relapsed AML. DLI may be combined with lymphodepleting agents or systemic chemotherapy such as hypomethylating agents \[[@B86-cancers-10-00179],[@B87-cancers-10-00179]\]. Once relapse has occurred after allo-grafting, survival is extremely poor (23% at one year) in all patients, with lower survival in older patients \[[@B88-cancers-10-00179]\]. Few studies have specifically addressed relapse and responses to post-relapse treatments in older populations. [Table 3](#cancers-10-00179-t003){ref-type="table"} lists some of the therapies which have been utilized in cases of relapse in older transplant recipients. Because of the difficulty in treatment of relapse post-transplant, there is interest in use of maintenance therapies such as hypomethylating agents or targeted inhibitors such as FLT3 inhibitors in appropriate populations at high risk of relapse. The impact these interventions will have on older transplant recipients and their tolerability remain to be explored. Use of reduced intensity conditioning regimens in this population could increase risk of relapse, and many older patients may enter transplant with higher disease burden after hypomethylating agents or fewer consolidation cycles, but this has not been systematically studied. [Table 3](#cancers-10-00179-t003){ref-type="table"} lists representative regimens which might be used post-transplant to maintain or treat AML relapse. Most of these have not been systematically studied in an older patient population. There is evidence that detecting minimal residual disease early after transplant can be used to trigger strategies to prevent emerging relapse \[[@B89-cancers-10-00179]\]. For example, in the RELAZA2 study, patients who had minimal residual disease detected after transplant were started on azacitidine \[[@B90-cancers-10-00179]\]. In the 26% of patients who were minimal residual disease positive, 40% had a decline of MRD and 19% had stable MRD after azacitidine at 6 months. Relapse eventually occurred in 33% but the median day of relapse was delayed until 397 days.

Many of these regimens have not been specifically examined in an older population, but they represent a spectrum of what has been used for prevention or treatment of relapse in older individuals. Second transplant or intensive chemotherapy is rarely used in older adults to treat post-transplant relapse. Immunomodulatory drugs have been examined but are thought to be associated with increased risk of graft-versus-host disease in patients with acute myeloid leukemia.

7. Research Gaps and Ongoing Studies {#sec7-cancers-10-00179}
====================================

There are many gaps in our knowledge in the field of allo-HCT for older patients with AML. To better guide the selection of older patients for allo-HCT, prospective trials need to incorporate patient-factors (e.g., physical function, comorbidity, nutritional status) and disease-factors (cytogenetic, molecular profile, etc.). There are also limited phase 3 randomized controlled trialss that compare the various conditioning regimens and alternative donor sources in older patients with AML. Multiple studies are ongoing that investigate various post-transplant maintenance strategies such as midostaurin (NCT02723435) or crenolanib (NCT01522469) in older patients with FLT3 activating mutations (NCT02723435). Although not limited to older patients, the BMT CTN 1506 study (NCT02997202) is currently investigating the use of gilteritinib as a maintenance therapy in patients with FLT3-internal tandem duplication AML. How best to treat GVHD in older transplant recipients has not been systemically studied and these studies have importance as GVHD may have greater impact on physical function in older transplant recipients \[[@B105-cancers-10-00179]\]. Research on why elder AML patients are not referred for transplant evaluation is also needed as regards patient preference, hematologist/oncologist bias, access to transplant centers, and status of disease. Lower intensity treatments such as hypomethylating agents are often considered palliative, but they may be used as a bridge to allo-HCT for older patients given the relative low toxicity compared to intensive induction chemotherapy \[[@B106-cancers-10-00179]\]. This strategy should be studied further.

8. Conclusions {#sec8-cancers-10-00179}
==============

Selected older patients with AML can benefit from allo-HCT, which provides the best chance for durable remission. Advances in the techniques and procedures of hematopoietic stem cell transplantation including alternate donor sources, reduced intensity conditioning regimens, and advanced strategies for preventing post-transplant relapse, have increased the availability and appropriateness of transplant for older adults with AML. Despite these advances, the number of older patients with AML who receive allo-HCT remains low. Further research is needed to improve candidate selection and access to donors, to optimize existing conditioning regimens, and to develop effective post-transplant maintenance strategies and treatment of relapsed disease.
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###### 

Examples of studies that compared the various conditioning regimens and included some patients aged 60 and over.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                          Study Design                  *N*              Conditioning Regimens   Age, Median (Range)   OS           NRM/TRM, %                         Relapse, %   Acute GVHD, %            Chronic GVHD, %
  ---------------------------------------------- ----------------------------- ---------------- ----------------------- --------------------- ------------ ---------------------------------- ------------ ------------------------ -----------------
  Aoudjhane 2005 \[[@B28-cancers-10-00179]\]     Retrospective                 722              MAC\                    54 (50--64)\          46\          32\                                24\          31\                      56\
                                                                                                RIC                     57 (50--73)           47\          18\                                41\          22\                      48\
                                                                                                                                              (2-year)     (2-year)                           (2-year)     (Grade II-IV, 100-day)   (Any, 2-year)

  Luger 2014 ^a^ \[[@B29-cancers-10-00179]\]     Retrospective                 5179\            MAC\                    42 (18--68)\          34\          18\                                32\          47\                      41\
                                                                               (AML: 3834)      RIC BM\                 51 (19--69)\          33\          16\                                42\          41\                      31\
                                                                                                RIC PBSC\               56 (18--70)\          33\          12\                                39\          45\                      45\
                                                                                                NMA                     57 (18--70)           26\          13\                                43\          47\                      41\
                                                                                                                                              (5-year)     (3-month; 35% for all by year 5)   (5-year)     (Grade II-IV, 100-day)   (Any, 5-year)

  Shimoni 2012 ^a^ \[[@B30-cancers-10-00179]\]   Prospective                   85\              MAC\                    49 (18--66)\          50\          18\                                40\          37\                      60\
                                                                               (AML: 50)        RIC                     60 (29--75)           44\          20\                                47\          25\                      47\
                                                                                                                                              (5-year)     (5-year)                           (5-year)     (Grade II-IV, 5-year)    (Any, 5-year)

  Scott 2017 ^a^ \[[@B31-cancers-10-00179]\]     Randomized controlled trial   272 (AML: 218)   MAC\                    55 (22--66)\          76 ^b^\      16 ^b^\                            16 ^b^\      45 ^c^\                  64 ^c^\
                                                                                                RIC                     55 (22--66)           63 ^b^\      4 ^b^\                             51 ^b^\      29 ^c^\                  48 ^c^\
                                                                                                                                              (18-month)   (18-month)                         (18-month)   (Grade II-IV, 100-day)   (Any, 18-month)

  Sebert 2015 \[[@B32-cancers-10-00179]\]        Prospective                   132              MAC\                    44 (35--56)\          43\          28\                                33\          61\                      \
                                                                                                RIC                     54 (37--66)           50\          21\                                38\          35\                      -\
                                                                                                                                              (4-year)     (4-year)                           (4-year)     (Grade II-IV, 120-day)   -

  Martino 2013 ^a^ \[[@B33-cancers-10-00179]\]   Retrospective                 878\             HyperMAC\               37 (18--60)\          51 ^d^\      27 ^e^\                            22 ^f^\      29\                      47\
                                                                               (AML: 864)       ConvMAC\                39 (21--63)\          56 ^d^\      22 ^e^\                            24 ^f^\      27\                      44\
                                                                                                RIC\                    54 (19--70)\          53 ^d^\      18 ^e^\                            34 ^f^\      25\                      48\
                                                                                                NMA                     56 (41--72)           29 ^d^\      29 ^e^\                            46 ^f^\      30\                      50\
                                                                                                                                              (7-year)     (7-year)                           (7-year)     (Any, 120-day)           (Any, 7-year)
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: AML, acute myeloid leukemia; GVHD, graft-versus-host disease; MAC, myeloablative conditioning; NMA, non-myeloablative; NRM, non-relapse mortality; OS, overall survival; RIC, reduced-intensity conditioning; TRM, treatment-related mortality; BM, bone marrow; PBSC, peripheral blood stem cell; hyperMAC, hyper-intensive myeloablative conditioning; convMAC, conventional myeloablative conditioning. ^a^ Study included patients with acute myeloid leukemia and myelodysplastic syndrome. ^b^ Patients with acute myeloid leukemia. ^c^ Patients with acute myeloid leukemia and myelodysplastic syndrome. ^d^ For patients over the age of 50, 7-year overall survival in the hyperintense myeloablative, conventional myeloablative, reduced-intensity, and non-myeloablative groups were 21%, 41%, 27%, and 31%, respectively. ^e^ For patients over the age of 50, 7-year non-relapse mortality in the hyperintense myeloablative, conventional myeloablative, reduced-intensity, and non-myeloablative groups were 51%, 41%, 24%, and 31%, respectively. ^f^ For patients over the age of 50, 7-year relapse rates in the hyperintense myeloablative, conventional myeloablative, reduced-intensity, and non-myeloablative groups were 28%, 22%, 29%, and 49%, respectively.
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###### 

Benefits and limitations of the various donor sources.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Donor Source           Benefits                                                                                                                   Limitations
  ---------------------- -------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Matched-sibling        Low rates of graft rejection.\                                                                                             Low availability of donors, especially in the older population \[[@B39-cancers-10-00179]\]
                         Lower risk of GVHD compared to unrelated donor                                                                             

  Matched-unrelated      Increased availability of donors.                                                                                          Donor search time can be prolonged \[[@B40-cancers-10-00179]\]\
                                                                                                                                                    May be extremely difficult to identify donor in ethnic/racial minorities \[[@B11-cancers-10-00179]\]\
                                                                                                                                                    Higher rates of GVHD when compared to matched sibling \[[@B41-cancers-10-00179]\]

  Haploidentical         Increased and rapid availability of donors.\                                                                               Increased risk of graft rejection\
                         Lower cost than UCB and unrelated donors\                                                                                  Risk of severe GVHD without adequate post-transplant prophylaxis (this is somewhat mitigated by use of post-transplant cyclophosphamide) \[[@B43-cancers-10-00179]\]
                         Availability of donor for future lymphocyte/stem cell donations.\                                                          
                         Comparable overall survival, relapse rates, and non-relapse mortality to other donor sources \[[@B42-cancers-10-00179]\]   

  Umbilical cord blood   Lower rates of acute and chronic GVHD\                                                                                     Delayed engraftment\
                         Donor search time is lower than matched unrelated donors \[[@B11-cancers-10-00179]\]                                       Increased risk of graft failure\
                                                                                                                                                    Lower quantity of harvest, need for adequate cell dose.\
                                                                                                                                                    Higher rates of infections due to slower engraftment and immune reconstitution \[[@B44-cancers-10-00179]\]\
                                                                                                                                                    No availability of future donor lymphocytes/stem cells
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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###### 

Representative Modalities Utilized Post-Transplant to Prevent or Treat Relapse.

  Intervention                                                                                       Examples
  -------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------
  Early tapering of immune suppression \[[@B91-cancers-10-00179]\]                                   
  Graded donor lymphocyte infusion (DLI) dosing \[[@B92-cancers-10-00179]\]                          
  Hypomethylating agents                                                                             Azacitidine \[[@B93-cancers-10-00179],[@B94-cancers-10-00179],[@B95-cancers-10-00179]\]
                                                                                                     Decitabine \[[@B96-cancers-10-00179]\]
  Hypomethylating agents and DLI \[[@B97-cancers-10-00179],[@B98-cancers-10-00179]\]                 
  FMS-like tyrosine kinase (FLT) 3 inhibitors                                                        Sorafenib \[[@B99-cancers-10-00179]\]
                                                                                                     Midostaurin \[[@B100-cancers-10-00179]\]
  Possibly B-cell lymphoma 2 (Bcl-2) inhibitors                                                      Venetoclax \[[@B101-cancers-10-00179]\]
  Possibly Isocitrate dehydrogenase (IDH) 2 inhibitors                                               Enasidenib \[[@B102-cancers-10-00179]\]
  Possibly checkpoint inhibitors or cytotoxic T-lymphocyte-associated protein (CTLA) 4 antagonists   Ipilimumab \[[@B103-cancers-10-00179]\]
  Regulatory T cells (Tregs) with azacitidine \[[@B104-cancers-10-00179]\]                           

[^1]: Co-first author.
